Emerging Biopharma
Flexible solutions. Responsive teams. Data-driven insights.


This conversation between Murray Aitken of the IQVIA Institute for Human Data Science and Meg Hooton of IQVIA Biotech offers a candid, data-grounded perspective on the pressures and opportunities facing emerging biotech companies today.
They explore trends in clinical trial activity, shifts in development productivity, the realities of new drug launches, evolving commercialization models, capital constraints, and what it will take for emerging biopharma to sustain innovation in an increasingly complex market environment.
Flexible solutions. Responsive teams. Data-driven insights.